About
IHP Therapeutics is developing IHP-102 for the treatment of acute vaso-occlusive crisis in sickle cell disease. Empowering individuals with sickle cell, IHP-102 aims to be the first self-administered rescue therapeutic, moving care to the home setting and avoiding costly and ill-equipped healthcare systems.
Our Team
Rinko Ghosh, MS, MBA
President and CEO
Jocelyn Jackson
CFO
Peggy McLaughlin
VP of Clinical Operations
Board of Directors
Rinko Ghosh, MS, MBA
​
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
​
​
Our Team
Rinko Ghosh, MS, MBA
President and CEO
John Paderi, PhD
CSO
Gabriel Njikang, PhD
CMC
Peggy McLaughlin
Clin. Ops. Advisor
Jocelyn Jackson
CFO
Kate Stuart, PhD
VP of Program Management
​
Nathan Bachtell, MD
Clinical Advisor
Robert Van Gorp
Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
​
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
​
​
Clinical and Scientific Advisors
Science
IHP-102 is a novel dual P-selectin and complement inhibitor, which are two key mechanisms of vaso-occlusion in sickle cell disease. During acute vaso-occlusive pain crises, blockade of these mechanisms shows strong promise for disease-modifying effect and could reduce both pain symptoms and the tissue and organ damage cause by this devastating condition.
Pipeline
Contact:
​
​
IHP Therapeutics has recently been made aware of a growing number of email scams targeting job candidates in the biotech industry. IHP exclusively uses @ihptherapeutics.com email addresses for any and all communication. We do not ask candidates to purchase anything, nor do we ask for any sensitive information via email. If a person claiming to represent IHP with an alternative email domain reaches out to you regarding a job posting, please report it to our team by emailing info@ihptherapeutics.com. Thank you.